TrialJournal of gynecologic oncology2021

Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.

Aikou Okamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.